OIRD in hospitalized patients is Atelerix’s first target indication for opioid-related unmet medical needs.
* Source: Medtronic Prodigy Study, 2020
– National Institutes of Health
Russian special forces soldiers are seen carrying out hostages killed by a highly potent weaponized opioid in a Moscow theatre after a three-day stand off with Chechen terrorists.
(Credit: Anton Denisov/AFP/Getty Images)
Much of the on-going research for the treatment of OIRD directly targets opioid receptors, with limited results; Atelerix’s ATLX-0199 technology takes a different approach.
*The Burden of OIRD-Related Adverse Drug Events on Hospitalized Previously Opioid-Free Surgical Patients, Richard D. Urman, MD; J Patient Safety, March 2021
Company has exclusive option on resulting intellectual property